The interaction of blood proteins with an implant surface is not only a basic occurrence, but it also Contributes greatly to a number of serious medical issues. Bacterial adherence can be facilitated by plasma proteins attaching to the surface of intravascular catheters, increasing the risk of local and systemic problems such catheter-related blood infections (CRBIs). This necessitates the creation of catheters that are both thrombogenic and antibacterial. S-nitroso-N-acetyl-penicillamine (SNAP) was integrated into ELASTON-E2As to create nitric oxide (NO) donor particles for use in catheters, in the current study. Nitric oxide has antithrombotic and antibacterial properties without contributing to medication resistance or cytotoxicity. The Fibrinogen, a protein found in blood plasma, was first coated on E2As-SNAP catheters that helps form clots and prevents bacteria from adhering to the implant surface. In vitro tests were performed to determine the catheters' suitability for biomedical applications, including contact angle, NO release kinetics, bacterial inhibition, and lack of cytotoxicity against mammalian cells. In a 24-hour investigation, the extremely on fibrinogen-coated catheters, hydrophobic catheters produced NO in the physiological range, which prevented bacteria from surviving for over 99 percent. The leachate from an E2AsSNAP catheter was not harmful when evaluated with conventional cytotoxicity assays using mouse fibroblasts. These findings suggest that the E2As-SNAP catheters are able to suppress live bacteria even with blood proteins present without causing cytotoxicity. In addition to medical devices that come in contact with blood, the principles of this study can also benefit other medical devices